Brian Loper: Okay. Excellent. All right. Let’s change channels again to Clyra. So at the Annual Shareholder Meeting a few months ago now, Steve, the executive over Clyra, was alluding to — yes. So we’re wondering if we’re allowed to talk about that news or what’s going on there?
Dennis Calvert: Yes, there’s a lot going on there. Remember, Clyra is the full — another full-circle story for the company like ONM. This is something we’ve been talking about since inception. And we finally got the money and regulatory approval and then the first clients in the marketplace. So there’s a couple of things going on. First is that there’s an independent sales force that’s been assembled, and they’re very interested in moving forward. And Steve and his team have started participating in marketing shows, where they’re presenting to physicians who can make yes decisions. And then there’s logistical things that have to happen behind that, like getting approved on formularies at surgery centers and hospitals. So there’s a lot of work in the setup before you can really go to scale, okay?
So that’s ongoing. And now with a little bit of capital, we’ve got resources to execute on that front. Second, the strategic partners that we’ve identified are very interested in moving forward. We’re very excited about it. The idea that the product could leap into an international — national adoption with global partners is something that’s very exciting to us. And we believe the innovation deserves to be positioned at that level. So we’re in deep in discussions on logistics terms, pricing, rights that you would expect with a potential program like that, and we’re very optimistic about its success. Of course, subject to being patient, while we negotiate with some very, very large companies to get their attention and get in the queue to launch product.
The beauty about this one is, as we said since inception, we believe the claims are disrupted by nature. And as we now are positioned for significant commercial success, we can see how the market over the last decade has been pushed towards us, as competitive products that have market share and have achieved some financial success are now falling under great pressure because of their potential toxicity, whether localized or systemic. And that market is shifting very rapidly, and it’s shifting towards Clyra. So just — let me just illustrate that for just a second. If you’re a company that has a product that’s creating a market, most companies die. If you’re creating a product that dislodges incumbents because of technical advance like ours, the proposition for success is exponentially higher, and that’s where we’re at.
We’re not having to create the market. The market has been established as a result of now the leaders having trouble with the basic technology of their solution and the extraordinary claims of Clyra’s product, namely biofilm efficacy, sustained release, up to treating antimicrobial residual activity, no cyto and no systemic tox, with performance that matches all rivals from a performance efficacy perspective, it stands out as the number one in the market. There’s a gap in that market, and we’re going to fill it. So we believe the most prudent thing for us to do is to negotiate for strategic partners that can really see that vision come real in a short period of time — shorter period of time and find the right partners that are culturally the same mindset and also will treat us in a fair way.
So we think that’s the vision for big success, and we think it’s right in front of us. So stay tuned, more information to come.
Brian Loper: All right. Appreciate that, Dennis. Yes, that — those are all the questions for now. So I appreciate you going over those.
Dennis Calvert: Yes. So do you want to do a closing then?
Brian Loper: Sure thing.
Dennis Calvert: Okay, everybody. Thanks for your time. We’re coming in just about 35 minutes, so hopefully, we’re succinct and complete. We welcome you to reach out, of course, e-mail us at info@biolargo.com. You can reach me directly. This is a very exciting time. I think the trending towards that 100%-plus growth rate is something that we’re striving for, for the year. And if the trend continues as represented, and with a little luck, some of these big contracts will come in. We’re going to see ‘23 and ‘24 shape up to be the best year in the history of the company. So we think it’s worth the wait and worth the effort, and I want to appreciate everyone for their support. Go, BioLargo.
Brian Loper: Thanks, Dennis.
Dennis Calvert: Thank you.
Operator: Thank you. This concludes today’s conference, and you may disconnect your lines at this time. Thank you for your participation.
